Claims for Patent: 9,181,572
✉ Email this page to a colleague
Summary for Patent: 9,181,572
Title: | Methods to modulate lysine variant distribution |
Abstract: | The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the distribution or amount of lysine variants expressed by host cells, as well as to compositions and processes for controlling the amount of lysine variants present in purified preparations. |
Inventor(s): | Subramanian; Kartik (Northborough, MA), Perez; Mayda (Worcester, MA), Zeng; Xiaobei (Carolina, PR), Wong; Chee Furng (Singapore, SG), Chumsae; Christopher (North Andover, MA) |
Assignee: | AbbVie, Inc. (North Chicago, IL) |
Application Number: | 13/830,976 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,181,572 |
Patent Claims: | 1. A method for producing a composition comprising adalimumab, comprising culturing a cell producing adalimumab in a cell culture media comprising an amount of one or more
basic amino acids sufficient to produce a composition comprising adalimumab in which less than 62% of the lysine variant species of adalimumab have zero C-terminal lysines (Lys 0).
2. The method of claim 1, wherein the one or more basic amino acids in the cell culture media is selected from the group consisting of arginine, lysine, histidine, ornithine and combinations thereof. 3. The method of claim 2, wherein the one or more basic amino acids in the cell culture media is ornithine. 4. The method of claim 2, wherein the one or more basic amino acids in the cell culture media is lysine. 5. The method of claim 4, wherein the lysine concentration in the cell culture media is 4 to 10 g/L. 6. The method of claim 2, wherein the one or more basic amino acids in the cell culture media is histidine. 7. The method of claim 1, wherein 61% or less of the lysine variant species have zero C-terminal lysines (Lys 0). 8. The method of claim 1, wherein 60% or less of the lysine variant species have zero C-terminal lysines (Lys 0). 9. The method of claim 1, wherein 58% or less of the lysine variant species have zero C-terminal lysines (Lys 0). 10. The method of claim 1, wherein 55% or less of the lysine variant species have zero C-terminal lysines (Lys 0). 11. The method of claim 1, wherein 48% or less of the lysine variant species have zero C-terminal lysines (Lys 0). 12. The method of claim 2, wherein the one or more basic amino acids in the cell culture media is arginine. 13. The method of claim 12, wherein the arginine concentration in the cell culture media is 6 to 9 g/L. 14. The method of claim 6, wherein the histidine concentration in the cell culture media is 8 g/L or more. 15. The method of claim 12, wherein the arginine concentration in the cell culture media is 6 g/L or more. 16. The method of claim 12, wherein the arginine concentration in the cell culture media is 8 g/L or more. 17. The method of claim 12, wherein the arginine concentration in the cell culture media is 9 g/L or more. 18. The method of claim 4, wherein the lysine concentration in the cell culture media is 4 g/L or more. 19. The method of claim 4, wherein the lysine concentration in the cell culture media is 8 g/L or more. 20. The method of claim 4, wherein the lysine concentration in the cell culture media is 10 g/L or more. 21. A method for producing a composition comprising adalimumab, comprising culturing a cell producing adalimumab in a cell culture media comprising an amount of lysine sufficient to produce a composition comprising adalimumab in which less than 62% of the lysine variant species of adalimumab have zero C-terminal lysines (Lys 0). 22. The method of claim 21, wherein the lysine concentration in the cell culture media is 4 to 10 g/L. 23. The method of claim 21, wherein the lysine concentration in the cell culture media is 4 g/L or more. 24. The method of claim 21, wherein the lysine concentration in the cell culture media is 8 g/L or more. 25. The method of claim 21, wherein the lysine concentration in the cell culture media is 10 g/L or more. 26. The method of claim 21, wherein 61% or less of the lysine variant species have zero C-terminal lysines (Lys 0). 27. The method of claim 21, wherein 55% or less of the lysine variant species have zero C-terminal lysines (Lys 0). 28. The method of claim 21, wherein 48% or less of the lysine variant species have zero C-terminal lysines (Lys 0). 29. A method for producing a composition comprising adalimumab, comprising culturing a cell producing adalimumab in a cell culture media comprising an amount of one or more basic amino acids sufficient to produce a composition comprising adalimumab wherein the sum of lysine variant species of adalimumab having one C-terminal lysine (Lys 1) and lysine variant species of adalimumab having two C-terminal lysines (Lys 2) is greater than 35%. 30. The method of claim 29, wherein the one or more basic amino acids in the cell culture media is selected from the group consisting of arginine, lysine, histidine, ornithine and combinations thereof. |
Details for Patent 9,181,572
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 12/31/2002 | ⤷ Try a Trial | 2032-04-20 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 02/21/2008 | ⤷ Try a Trial | 2032-04-20 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 04/24/2013 | ⤷ Try a Trial | 2032-04-20 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.